Indivior Pharmaceuticals, Inc. Net Income Loss

Quick Answer

Indivior Pharmaceuticals, Inc. reported Net Income Loss of $210.00 million for the year ending 2025.

  • Indivior Pharmaceuticals, Inc. showed an increase of +2,900.0% in Net Income Loss from 2024 to 2025.
  • This data is from Indivior Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
  • XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 4 years of available data (2022 to 2025), Indivior Pharmaceuticals, Inc.'s Net Income Loss has grown by 577.3%.
  • Historical annual values: Fiscal year 2025: $210.00 million | Fiscal year 2024: $7.00 million | Fiscal year 2023: -$126.00 million | Fiscal year 2022: -$44.00 million.
  • Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: